• Former President Donald Trump has announced a 100% tariff on branded pharmaceuticals effective October 1, 2025, unless companies are actively building U.S. manufacturing facilities.
  • The administration is pushing a "most favored nation" policy requiring U.S. drug prices to match the lowest international prices, with a September 29 opt-in deadline.
  • Generic drugs, representing 90% of U.S. prescriptions, are exempt from the tariffs, while European imports face only a 15% levy.

Mounting Pressure on Drug Makers

The Trump administration is turning up the heat on pharmaceutical companies with a series of escalating tariffs designed to force lower drug prices and reshore manufacturing operations. The centerpiece of the policy is a sweeping 100% tariff on branded or patented pharmaceuticals set to take effect October 1, 2025, unless companies can demonstrate they are actively constructing manufacturing facilities within the United States.

According to people familiar with the matter, the administration is giving companies a narrow path to avoid the punitive measures. "The exemption criteria are specifically tied to concrete, verifiable progress in building or expanding U.S. production capacity," said one official who asked not to be identified discussing internal policy. Companies that fail to meet these requirements by the deadline would face the full tariff burden on their imported branded medications.

Industry Divergence and Market Impact

The policy creates a stark divide within the pharmaceutical sector. While generic drugs, which constitute approximately 90% of U.S. prescriptions, are completely exempt from the new tariffs, the burden falls disproportionately on branded drug manufacturers without domestic production. European imports face a more modest 15% tariff, reflecting ongoing trade negotiations and existing supply dependencies.

Major players including Johnson & Johnson, Merck, Novo Nordisk, and Pfizer are already responding to the pressure. Pfizer is expected to announce both lower prices on certain medications and a substantial $70 billion U.S. manufacturing investment in the coming weeks, according to people briefed on the matter.

Meanwhile, the Biotechnology Innovation Organization has warned that smaller biotech firms producing niche products abroad could face existential threats. "For companies without the capital to rapidly build U.S. facilities, this creates an impossible situation," said a representative from the trade group who declined to be named while negotiations continue.

Parallel Pricing Push

Running alongside the tariff threat is the administration's renewed push for a "most favored nation" pricing model that would require U.S. drug prices to align with the lowest prices offered in other developed countries. Companies have until September 29 to voluntarily opt into this framework, though administration officials have suggested that future regulatory actions could make compliance mandatory.

The dual approach represents one of the most aggressive attempts to reshape pharmaceutical markets in decades. "What we're seeing is the use of both trade policy and pricing pressure to achieve what legislation has failed to accomplish," noted a healthcare policy analyst who requested anonymity to speak freely about the developments.

Efforts to reach representatives from several major pharmaceutical companies for comment were not immediately successful. The administration has set a tight timeline for compliance, leaving many manufacturers scrambling to assess their options as the September deadline for the MFN policy approaches and the longer-term tariff threat looms.

Correction: An earlier version of this article misstated the percentage of U.S. prescriptions filled by generic drugs. The correct figure is approximately 90%.